Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Amoxicillin-clavulanate→

Amoxicillin-clavulanate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
79198-29-1
PubChem CID
6435924
Molecular formula
C24H28N4O10S
Molecular weight
564.6 g/mol
Drug class
Combination antibacterial: aminopenicillin (amoxicillin) plus beta-lactamase inhibitor (clavulanic acid)
Mechanism of action
Amoxicillin binds penicillin-binding proteins and inhibits bacterial peptidoglycan cell-wall synthesis, causing cell-wall weakening and lysis. Clavulanic acid inactivates certain beta-lactamases and protects amoxicillin from enzymatic degradation; it has no clinically useful antibacterial action alone.
Indications / reported uses
  • Treatment of infections caused by susceptible organisms, including selected respiratory, ear/nose/throat, urinary, skin/soft-tissue, dental and bone/joint infections; the exact indications vary by strength, formulation and local product information

Sources: UK SmPC — Co-amoxiclav 500 mg/125 mg · UK SmPC — Co-amoxiclav 875 mg/125 mg · NCBI Bookshelf — Amoxicillin/clavulanate pharmacology · FDA product information

Identification source: PubChem record (CID 6435924). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Amoxicillin-clavulanate Environmental Risk Assessment (ERA) (the Amoxicillin-clavulanate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.